Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) — atai Life…


Previous articleField Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Next articleMydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients